Frequent factor II G20210A mutation in idiopathic portal vein thrombosis

被引:86
作者
Chamouard, P [1 ]
Pencreach, E
Maloisel, F
Grunebaum, L
Ardizzone, JF
Meyer, A
Gaub, MP
Goetz, J
Baumann, R
Uring-Lambert, S
Levy, S
Dufour, P
Hauptmann, G
Oudet, P
机构
[1] Hop Hautepierre, Serv Hepatogastroenterol & Assistance Nutrit, F-67098 Strasbourg, France
[2] Hop Hautepierre, Lab Immunol & Hematol, F-67098 Strasbourg, France
[3] Hop Hautepierre, Serv Oncohematol, F-67098 Strasbourg, France
[4] Hop Hautepierre, Biochim Lab, Unite Fonct Biol Mol, Strasbourg, France
关键词
D O I
10.1016/S0016-5085(99)70238-6
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Despite extensive investigations of portal vein thrombosis, no underlying cause is identifiable in up to 30% of patients. A recently described mutation of the prothrombin gene at nucleotide position 20210 is associated with history of venous thrombosis and was assessed in this study. Methods: We compared the frequency of factor II G20210A and factor V G1691A (factor V Leiden) mutations in 10 patients with idiopathic portal vein thrombosis, 10 patients with nonidiopathic portal vein thrombosis, 60 patients with deep vein thrombosis of the legs, and 42 control subjects. Results: The frequency of factor II G20210A mutation was increased in patients with idiopathic portal vein thrombosis (40.0%; confidence interval, 3.1%-76.9%) compared with controls (4.8%; confidence interval, 0%-11.5%) or patients with nonidiopathic portal vein thrombosis or deep vein thrombosis (P = 0.0001). In contrast, the frequency of the factor V G1691A mutation was similar in subjects with portal vein thrombosis and in controls but was increased in patients with deep vein thrombosis (P = 0.0001). Conclusions: The factor II G20210A mutation is frequent in patients with idiopathic portal vein thrombosis and should therefore be assessed under this circumstance.
引用
收藏
页码:144 / 148
页数:5
相关论文
共 27 条
  • [1] BAROSI G, 1991, CANCER, V68, P2310, DOI 10.1002/1097-0142(19911115)68:10<2310::AID-CNCR2820681034>3.0.CO
  • [2] 2-2
  • [3] BERLIN NI, 1986, SEMIN HEMATOL, V23, P131
  • [4] MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C
    BERTINA, RM
    KOELEMAN, BPC
    KOSTER, T
    ROSENDAAL, FR
    DIRVEN, RJ
    DERONDE, H
    VANDERVELDEN, PA
    REITSMA, PH
    [J]. NATURE, 1994, 369 (6475) : 64 - 67
  • [5] PROTHROMBIN SALAKTA - AN ABNORMAL PROTHROMBIN CHARACTERIZED BY A DEFECT IN THE ACTIVE-SITE OF THROMBIN
    BEZEAUD, A
    DROUET, L
    SORIA, C
    GUILLIN, MC
    [J]. THROMBOSIS RESEARCH, 1984, 34 (06) : 507 - 518
  • [6] CARDOT F, 1992, GASTROEN CLIN BIOL, V16, P644
  • [7] FAMILIAL THROMBOPHILIA DUE TO A PREVIOUSLY UNRECOGNIZED MECHANISM CHARACTERIZED BY POOR ANTICOAGULANT RESPONSE TO ACTIVATED PROTEIN-C - PREDICTION OF A COFACTOR TO ACTIVATED PROTEIN-C
    DAHLBACK, B
    CARLSSON, M
    SVENSSON, PJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (03) : 1004 - 1008
  • [8] Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients
    De Stefano, V
    Chiusolo, P
    Paciaroni, K
    Casorelli, I
    Rossi, E
    Molinari, F
    Servidei, S
    Tonali, PA
    Leone, G
    [J]. BLOOD, 1998, 91 (10) : 3562 - 3565
  • [9] Denninger MH, 1997, THROMB HAEMOSTASIS, V78, P1297
  • [10] PAROXYSMAL NOCTURNAL HEMOGLOBINURIA ASSOCIATED WITH HEPATIC AND PORTAL VENOUS THROMBOSIS
    GROSSMAN, JA
    MCDERMOTT, WV
    [J]. AMERICAN JOURNAL OF SURGERY, 1974, 127 (06) : 733 - 736